BeyondSpring (BYSI) Competitors $1.64 +0.00 (+0.26%) Closing price 04/25/2025 03:58 PM EasternExtended Trading$1.65 +0.00 (+0.30%) As of 04/25/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BYSI vs. PROK, CADL, CRGX, DSGN, ENGN, PLX, OCGN, AMRN, NVCT, and MDWDShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include ProKidney (PROK), Candel Therapeutics (CADL), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), enGene (ENGN), Protalix BioTherapeutics (PLX), Ocugen (OCGN), Amarin (AMRN), Nuvectis Pharma (NVCT), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. ProKidney Candel Therapeutics CARGO Therapeutics Design Therapeutics enGene Protalix BioTherapeutics Ocugen Amarin Nuvectis Pharma MediWound ProKidney (NASDAQ:PROK) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment. Which has higher earnings & valuation, PROK or BYSI? BeyondSpring has higher revenue and earnings than ProKidney. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$76K3,928.32-$35.47M-$0.63-1.62BeyondSpring$1.88M35.35-$21.03MN/AN/A Does the MarketBeat Community favor PROK or BYSI? BeyondSpring received 177 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% BeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Is PROK or BYSI more profitable? Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% BeyondSpring N/A N/A N/A Which has more volatility and risk, PROK or BYSI? ProKidney has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Do insiders & institutionals believe in PROK or BYSI? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor PROK or BYSI? In the previous week, ProKidney had 3 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for ProKidney and 1 mentions for BeyondSpring. ProKidney's average media sentiment score of 1.92 beat BeyondSpring's score of 1.87 indicating that ProKidney is being referred to more favorably in the media. Company Overall Sentiment ProKidney Very Positive BeyondSpring Very Positive Do analysts prefer PROK or BYSI? ProKidney presently has a consensus price target of $5.00, suggesting a potential upside of 390.20%. Given ProKidney's stronger consensus rating and higher possible upside, equities analysts plainly believe ProKidney is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryProKidney beats BeyondSpring on 9 of the 14 factors compared between the two stocks. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.32M$6.70B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.30%P/E RatioN/A7.2022.3718.43Price / Sales35.35239.17391.12101.46Price / CashN/A65.8538.1834.62Price / Book-1.816.306.684.19Net Income-$21.03M$142.95M$3.22B$248.05M7 Day Performance25.57%8.00%6.24%6.53%1 Month Performance10.40%-4.16%-2.82%-2.16%1 Year Performance-22.77%-2.77%16.46%4.71% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.65+0.3%N/A-27.5%$66.32M$1.88M0.0080Positive NewsPROKProKidney2.3503 of 5 stars$0.73-7.3%$5.00+582.2%-62.4%$214.52M$76,000.00-1.333Insider TradeGap UpCADLCandel Therapeutics2.0654 of 5 stars$4.51-1.3%$21.00+365.6%-22.6%$213.03M$120,000.00-2.6160CRGXCARGO Therapeutics2.9814 of 5 stars$4.60-0.9%$15.00+226.1%-75.3%$211.84MN/A-1.08116Positive NewsHigh Trading VolumeDSGNDesign Therapeutics1.5235 of 5 stars$3.59+2.6%$8.00+122.8%+3.2%$203.78MN/A-4.2240News CoverageGap DownENGNenGene2.5521 of 5 stars$3.99-0.3%$24.13+504.6%-73.6%$203.40MN/A-6.8831Short Interest ↑PLXProtalix BioTherapeutics2.6287 of 5 stars$2.55-2.3%$15.00+488.2%+141.5%$198.98M$53.40M-19.62200News CoveragePositive NewsOCGNOcugen0.9745 of 5 stars$0.68-0.3%$6.33+835.4%-39.1%$197.72M$4.06M-3.7680AMRNAmarin0.522 of 5 stars$9.55+4.8%$7.00-26.7%-39.4%$196.10M$228.61M-106.11360Short Interest ↓Analyst RevisionNVCTNuvectis Pharma2.5883 of 5 stars$8.34-5.9%$15.67+87.8%+61.1%$195.09MN/A-7.198News CoverageMDWDMediWound1.231 of 5 stars$17.65+3.2%$31.33+77.5%+2.4%$190.76M$20.22M-6.0980News Coverage Related Companies and Tools Related Companies PROK Competitors CADL Competitors CRGX Competitors DSGN Competitors ENGN Competitors PLX Competitors OCGN Competitors AMRN Competitors NVCT Competitors MDWD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BYSI) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BYSI Stock Free BYSI Stock Alerts